Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$37 Mln
P/E Ratio
--
P/B Ratio
3.07
Industry P/E
--
Debt to Equity
0
ROE
-1.8 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-2.58
CFO
$-188.24 Mln
EBITDA
$-253.94 Mln
Net Profit
$-202.90 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Akari Therapeutics plc ADS - ADR
| 18.03 | -5.88 | 18.03 | 19.01 | -60.06 | -46.22 | -37.16 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Akari Therapeutics plc ADS - ADR
| -60.60 | -66.80 | -68.67 | -18.92 | 5.71 | 11.46 | -63.54 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 9,808.03 | 20.22 | 23.13 | |
| 295.46 | 8,956.09 | 22.08 | 58.42 | |
| 26.65 | 9,559.25 | -- | -28.77 | |
| 105.01 | 10,030.35 | 30.81 | 14.16 |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents... inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts. Address: 22 Boston Wharf Road, Boston, MA, United States, 02210 Read more
President, CEO & Director
Ms. Rachelle Suzanne Jacques
Interim President, CEO & Director
Dr. Samir Rashmikant Patel M.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Akari Therapeutics plc ADS - ADR stood at $ 12 Mln as on 30-Sep-24
The share price of Akari Therapeutics plc ADS - ADR is $1.44 (NASDAQ) as of 24-Apr-2025 10:11 EDT. Akari Therapeutics plc ADS - ADR has given a return of -60.06% in the last 3 years.
Akari Therapeutics plc ADS - ADR has a market capitalisation of $ 37 Mln as on 22-Apr-2025. As per Value Research classification, it is a company.
The P/B ratio of Akari Therapeutics plc ADS - ADR is 3.07 times as on 22-Apr-2025, a 40% premium to its peers’ median range of 2.20 times.
Since, TTM earnings of Akari Therapeutics plc ADS - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Akari Therapeutics plc ADS - ADR and enter the required number of quantities and click on buy to purchase the shares of Akari Therapeutics plc ADS - ADR.
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts. Address: 22 Boston Wharf Road, Boston, MA, United States, 02210
The CEO & director of Ms. Rachelle Suzanne Jacques. is Akari Therapeutics plc ADS - ADR, and CFO & Sr. VP is Dr. Samir Rashmikant Patel M.D..
There is no promoter pledging in Akari Therapeutics plc ADS - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Akari Therapeutics plc ADS - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Akari Therapeutics plc ADS - ADR was $0 Mln.
$-0.01
(
